Abstract
Importance Disease prevalence estimation is highly sensitive to sample characteristics shaped by recruitment and data collection strategies. Using follow-up study modules that require active participant engagement may introduce participation bias, affecting the accuracy of disease prevalence estimation.
Objective To estimate the prevalence of ischemic heart disease (IHD) and stroke using electronic health records (EHR) and the self-reported Personal Medical History (PMH) survey collected in the All of Us Research Program.
Design and settings Cross-sectional study aimed at estimating the prevalence of IHD and stroke among 266,472 participants with EHR in the latest release of the All of Us Registered Tier Curated Data Repository (R2022Q4R9).
Main outcomes and measures Primary outcomes were IHD and stroke, ascertained using expert-curated diagnostic and procedure codes recorded in EHR. Secondary outcomes were IHD and stroke, ascertained using responses from the PMH survey. To mitigate the impact of participation bias in the PMH survey responses, we applied poststratification weighting based on annual household income and education.
Results Of the 266,472 participants with EHR, 17,054 (6.4%) were identified as having IHD and 7,461 (2.8%) as having stroke based on the EHR definitions. Among PMH survey respondents, the EHR-based prevalence was lower at 5.6% (95% CI, 5.4-5.7) for IHD and 2.2% (95% CI, 2.1-2.3) for stroke, compared to 7.2% (95% CI, 7.0-7.3) for IHD and 3.3% (95% CI, 3.2-3.4) for stroke among non-respondents. The PMH survey-based prevalence among respondents was 5.9% (95% CI, 5.7-6.0) for IHD and 3.6% (95% CI, 3.5-3.7) for stroke, with higher estimates among non-Hispanic White participants after applying poststratification weights. Conclusion and relevance: Our findings suggest that while the current All of Us cohort with EHR reflects the general US population for IHD and stroke prevalence, participants completing the PMH survey are skewed toward higher socioeconomic status and medical literacy. Future research should refine bias mitigation strategies when using voluntary follow-up data to estimate disease prevalence in this cohort.
Question What is the prevalence of ischemic heart disease (IHD) and stroke in the All of Us Research Program cohort with electronic health records (EHR), and in the subset of these participants who also completed the Personal Medical History (PMH) survey?
Findings The EHR-based prevalence estimates of IHD and stroke were 6.4% and 2.8%, respectively. They were significantly lower among PMH survey respondents but higher among non-respondents.
Meaning Participants who complete follow-up study modules, such as the PMH survey, may disproportionately represent those with higher socioeconomic status and better health, potentially leading to an underestimation of IHD and stroke prevalence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by funding through the National Institutes of Health, Office of the Director (OT2OD026553). In addition, the All of Us Research Program would not be possible without the contributions made by its participants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used data available through the All of Us Researcher Workbench (https://workbench.researchallofus.org/) for the Registered Tier access (R2022Q4R9), a cloud-based platform where approved researchers can access and analyze data collected from the All of Us participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The second author's name was misspelled but has now been corrected.
Data Availability
Access to the Registered and Controlled Tier data is restricted to US-based researchers whose institutions have signed a Data Use and Registration Agreement (DURA) and who have verified their identity.
